ABC.L Regulatory News (ABC)

1 May 2008 07:01

ABCAM Plc01 May 2008 For immediate release 01 May 2008 ABCAM PLC ("Abcam" or "the Company") Trading Update The Board of Abcam plc (AIM: ABC), the rapidly growing bioscience company thatmarkets antibodies via its own online catalogue, is pleased to provideshareholders with a trading update. Sales growth, so far, in the second half of the financial year has beenparticularly strong as a result of higher volumes, improved pricing andbeneficial exchange rate movements, particularly in the Euro/£ rate. As a resultsales are now expected to be ahead of market expectations and the outlook forthe profit for the full year to 30 June 2008 has improved significantly. Jonathan Milner, Abcam's Chief Executive Officer, said: "We have beenparticularly pleased by the momentum in our sales growth across all of ourgeographies. This momentum is a reflection of the growth in the researchantibody market, of the strength of the Abcam brand and of our leadership in theselection of antibodies of particular scientific interest." For further information please contact: Abcam + 44 (0) 1223 696000Jonathan Milner, Chief Executive OfficerJeff Iliffe, Chief Financial Officerwww.abcam.com Numis Securities + 44 (0) 20 7776 1500James Black/Nick Westlake Buchanan Communications + 44 (0) 20 7466 5000Mark Court / Mary-Jane Johnson Notes for editors: About Abcam plc Abcam is a producer and distributor of research-grade antibodies headquarteredin Cambridge, UK, with a US office located in Cambridge, Massachusetts and aJapanese office in Tokyo. Abcam was admitted to AIM in November 2005 and tradesunder the ticker symbol ABC. The Company produces and distributes its own andthird party produced antibodies to academic and commercial users throughout theworld with product information provided and ordering available through theCompany's website, www.abcam.com. The antibodies are sold under the Abcam brandname. The Company's vision is to build the largest online antibody resource inthe world while also ensuring that the antibodies are of high quality andcommercially viable. Abcam now has an online catalogue of approximately 42,000products, most of which are antibodies, from over 200 suppliers supported byup-to-date and detailed technical data sheets, which are created by the Company.The Company currently employs 176 staff in its three operating companies. This information is provided by RNS The company news service from the London Stock Exchange